Therefore, flavonoids can potentially be used as primary compounds to design nonretinoids for the treatment of retinal degeneration associated with rhodopsin mutations (Herrera-Hernandez et al., 2017; Ortega et al., 2019, 2022). The gene discussed is RHO; the disease is retinal degeneration.